Search research articles
Contact Us
Filters
Showing results (11-20 of 85) with videos related to
Page
of 9
Sort By:
The Oncologist
|
April 24, 2014
Are we ready for the 10% solution?
Helen X Chen, Larry V Rubinstein, Lalitha K Shankar, et al.
Journal for Immunotherapy of Cancer
|
July 6, 2021
Ocular adverse events in PD-1 and PD-L1 inhibitors
LeAnne Young, Shanda Finnigan, Howard Streicher, et al.
Nature Reviews. Drug Discovery
|
October 30, 2010
Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements
Shivanni Kummar, Helen X Chen, John Wright, et al.
Clinical Colorectal Cancer
|
January 7, 2011
Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma
Allyson J Ocean, Blase Polite, Paul Christos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2006
Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301
Helen X Chen, Margaret Mooney, Matthew Boron, et al.
Gynecologic Oncology
|
September 15, 2010
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment
Stephanie V Blank, Paul Christos, John P Curtin, et al.
JAMA Network Open
|
December 1, 2020
Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti-PD1/PDL1 Clinical Trials
Joshua E Reuss, Diana Stern, Jared C Foster, et al.
American Journal of Clinical Oncology
|
May 12, 2010
A pilot study of bevacizumab and interferon-α2b in ocular melanoma
Kristan D Guenterberg, Valerie P Grignol, Kiran V Relekar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 3, 2012
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors
Aung Naing, Patricia LoRusso, Siqing Fu, et al.
The New England Journal of Medicine
|
August 2, 2003
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
James C Yang, Leah Haworth, Richard M Sherry, et al.
Page
of 9
Search research articles
Search
Showing results (11-20 of 85) with videos related to
Sort By:
Page
of 9
The Oncologist
|
April 24, 2014
Are we ready for the 10% solution?
Helen X Chen, Larry V Rubinstein, Lalitha K Shankar, et al.
Journal for Immunotherapy of Cancer
|
July 6, 2021
Ocular adverse events in PD-1 and PD-L1 inhibitors
LeAnne Young, Shanda Finnigan, Howard Streicher, et al.
Nature Reviews. Drug Discovery
|
October 30, 2010
Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements
Shivanni Kummar, Helen X Chen, John Wright, et al.
Clinical Colorectal Cancer
|
January 7, 2011
Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma
Allyson J Ocean, Blase Polite, Paul Christos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2006
Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301
Helen X Chen, Margaret Mooney, Matthew Boron, et al.
Gynecologic Oncology
|
September 15, 2010
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment
Stephanie V Blank, Paul Christos, John P Curtin, et al.
JAMA Network Open
|
December 1, 2020
Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti-PD1/PDL1 Clinical Trials
Joshua E Reuss, Diana Stern, Jared C Foster, et al.
American Journal of Clinical Oncology
|
May 12, 2010
A pilot study of bevacizumab and interferon-α2b in ocular melanoma
Kristan D Guenterberg, Valerie P Grignol, Kiran V Relekar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 3, 2012
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors
Aung Naing, Patricia LoRusso, Siqing Fu, et al.
The New England Journal of Medicine
|
August 2, 2003
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
James C Yang, Leah Haworth, Richard M Sherry, et al.
Page
of 9